Bristol-Myers fires researchers, exits three therapy areas in R&D overhaul
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb is firing some of its scientists and abandoning three areas of early-stage research, including diabetes, to focus on cancer and other therapeutic targets.